- Home
- MCRB vs RAND Comparison
MCRB vs RAND Comparison
Compare MCRB & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- RAND
- Stock Information
- Founded
- MCRB 2010
- RAND 1969
- Country
- MCRB United States
- RAND United States
- Employees
- MCRB N/A
- RAND N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- MCRB Health Care
- RAND Finance
- Exchange
- MCRB Nasdaq
- RAND Nasdaq
- Market Cap
- MCRB 72.0M
- RAND 57.6M
- IPO Year
- MCRB 2015
- RAND N/A
- Fundamental
- Price
- MCRB $7.05
- RAND $16.25
- Analyst Decision
- MCRB Hold
- RAND
- Analyst Count
- MCRB 5
- RAND 0
- Target Price
- MCRB $73.67
- RAND N/A
- AVG Volume (30 Days)
- MCRB 93.5K
- RAND 5.9K
- Earning Date
- MCRB 05-07-2025
- RAND 05-05-2025
- Dividend Yield
- MCRB N/A
- RAND 7.14%
- EPS Growth
- MCRB N/A
- RAND 39.77
- EPS
- MCRB 8.98
- RAND 3.12
- Revenue
- MCRB N/A
- RAND $8,499,970.00
- Revenue This Year
- MCRB N/A
- RAND N/A
- Revenue Next Year
- MCRB N/A
- RAND N/A
- P/E Ratio
- MCRB $0.84
- RAND $5.21
- Revenue Growth
- MCRB N/A
- RAND 12.52
- 52 Week Low
- MCRB $6.53
- RAND $14.01
- 52 Week High
- MCRB $30.60
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- MCRB 38.95
- RAND 41.76
- Support Level
- MCRB $7.32
- RAND $15.50
- Resistance Level
- MCRB $7.86
- RAND $16.84
- Average True Range (ATR)
- MCRB 0.63
- RAND 1.12
- MACD
- MCRB 0.10
- RAND -0.03
- Stochastic Oscillator
- MCRB 28.89
- RAND 23.43
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.